Stock Analiz

Maxcyte, Inc. MXCT

Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026

$1.19Market cap $123M
Open the interactive analysis →

Maxcyte, Inc. (MXCT) is a healthcare company listed in the US with a market value of about $123M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of -$28M, a net margin of -81.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -14%.

About Maxcyte

Maxcyte is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $22M in 2019 to $33M in 2025, growth of about 7.3% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 5% over three years (dilution for shareholders). It spends 63% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.6
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-14.5%
Revenue growth (5 yrs, per year)4.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-88.6%
ROIC (5-yr avg.)-13.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$34M$33M$39M$41M$44M$34M$26M$22M
Net income-$28M-$45M-$41M-$38M-$24M-$19M-$12M-$13M
Free cash flow-$21M-$36M-$29M-$25M-$33M-$15M-$11M-$10M
EPS (diluted)$-0.26$-0.42$-0.39$-0.37$-0.23$-0.21$-0.17$-0.23
Net margin-81.4%-135.1%-106.3%-91.8%-53.2%-56.3%-45.1%-59.6%
ROIC—-21.6%-18.0%-15.2%-8.0%-5.3%-21.9%-72.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Maxcyte pay a dividend?

Not currently.

Is Maxcyte a good stock to buy?

We do not give buy or sell advice. Maxcyte scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.